['urinary bladder overactive', 'overactive bladder', 'urgency incontinence', 'urinary bladder diseases\\urologic diseases']
['solifenacin succinate', 'mirabegron', 'placebo to match solifenacin', 'placebo to match mirabegron']

        Inclusion Criteria:

        Main Inclusion at Screening (Visit 1):

          -  Subject had completed study 178-CL-101 or study 905-EC-012 (This inclusion criterion
             would no longer apply once the recruitment for study 178-CL-101 and study 905-EC-012
             had been completed. In that case the subject had to have symptoms of "wet" OAB
             (urinary frequency and urgency with incontinence) for at least 3 months);

          -  Subject was willing and able to complete the micturition diary and questionnaires
             correctly and able to measure his/her vital signs at home at stipulated time points,
             using the device provided by the study personnel, and to adequately record the
             readings;

        Main Inclusion at Randomization (Visit 2):

          -  Subject had a micturition frequency of on average ≥ 8 times per 24-hour period during
             the last 7 days of the micturition diary period (incontinence episode should not be
             counted as a micturition).

          -  Subject had experienced at least 3 incontinence episodes during the last 7 days of the
             micturition diary period.

          -  Subject had experienced on average at least 1 urgency episode (grade 3 or 4 on Patient
             Perception of Intensity of Urgency Scale [PPIUS]) per 24-hour period during the 7-day
             micturition diary period.

        Exclusion Criteria:

        Main Exclusion at Screening (Visit 1):

          -  Subject had clinically significant bladder outflow obstruction at risk of urinary
             retention;

          -  Subject had significant PVR volume (> 150 mL);

          -  Subject had significant stress incontinence or mixed stress/urgency incontinence where
             stress is the predominant factor;

          -  Subject has an indwelling catheter or practices intermittent self-catheterization;

          -  Subject had evidence of a UTI (urine culture containing > 100,000 cfu/mL), chronic
             inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation
             therapy or previous or current malignant disease of the pelvic organs;

          -  Subject had intravesical treatment in the past 12 months with e.g., botulinum toxin,
             resiniferatoxin, capsaicin;

        Main Exclusion at Randomization (Visit 2):

          -  Subject had evidence of a urinary tract infection (UTI) (urine culture containing >
             100,000 cfu/mL) as assessed in the Screening visit (V1) samples. The subject could be
             rescreened after successful treatment of the UTI (confirmed by a dipstick negative for
             nitrite).

          -  Subject had an average total daily urine volume > 3000 mL as recorded in the
             micturition diary period.
      